MedTrace Logo

A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients

NCT05561491 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-06-22

No results posted yet for this study

Summary

A Phase 2 study investigating the efficacy and safety of ONCOS-102 alone or in combination with balstilimab (a programmed death receptor-1 \[PD-1\] inhibitor).

Conditions

Interventions

BIOLOGICAL

ONCOS-102

Oncolytic virus

BIOLOGICAL

Balstilimab

Anti PD-1

Sponsors & Collaborators

  • Agenus Inc.

    collaborator INDUSTRY

  • Targovax Oy

    lead INDUSTRY

Principal Investigators

  • Douglas B Johnson, MD, MSCI · Vanderbilt Institute for Infection, Immunology and Inflammation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-31
Primary Completion
2027-06-30
Completion
2027-06-30
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05561491 on ClinicalTrials.gov